Core Insights - The inclusion of "medical beauty services" in the CPI marks a significant shift for the industry, transitioning from a niche service to a recognized component of the national economic monitoring system [3][19] - The implementation of the new VAT regulations explicitly excludes profit-driven medical beauty institutions from tax exemptions, reinforcing their classification as commercial services and eliminating tax arbitrage opportunities [3][19] - These dual policy adjustments signify a transition from "wild growth" to "regulated development," fundamentally restructuring the competitive landscape and development logic of the medical beauty industry [3][19] Market Dynamics - The medical beauty market is experiencing "differentiated growth," with leading chain institutions achieving growth through refined operations, while smaller institutions face significant operational pressures [5][21] - In the first half of 2025, over 63% of medical beauty institutions reported revenue declines, with only 14% achieving growth; Q2 was particularly challenging, with 58% of institutions experiencing declines [5][21] - The average customer spending in the medical beauty industry dropped to 6,500 yuan, a 10% decrease year-on-year, while the frequency of consumer visits increased, indicating a trend towards more conservative spending among middle and high-income consumers [5][21] Consumer Trends - The trend of "popularization and down-market penetration" is becoming increasingly evident, with lower-tier cities emerging as new growth engines for the industry [6][22] - By 2025, the proportion of medical beauty institutions in third-tier cities and below increased from 30% in 2022 to 42%, with overall consumption growth reaching 22%, double that of first-tier cities [6][22] - Non-surgical light medical beauty projects have become the mainstream, accounting for over 53% of the market, with a market size of 227.9 to 258 billion yuan, driving industry growth [6][22] Regulatory Environment - The simultaneous implementation of the CPI inclusion and new VAT regulations represents a policy "one-two punch" for the regulated development of the medical beauty industry, establishing its commercial consumption attributes [8][24] - This regulatory shift has eliminated the "gray area" label that has long plagued the industry, with the CPI now monitoring price fluctuations and consumption scale as part of national economic management [9][25] - The combination of these policies is transforming the identity of the medical beauty industry from "marginal service" to "mainstream consumption," laying the groundwork for its regulated development [10][26] Competitive Landscape - The regulatory changes are leading to a "good money driving out bad money" scenario, where compliant institutions benefit from favorable conditions while non-compliant ones face significant operational challenges [11][27] - Over 18,000 non-compliant institutions were shut down in 2025, and more than 320 violators had their licenses revoked, indicating the effectiveness of ongoing regulatory measures [11][27] - The market is shifting from a seller's market to a buyer's market, with price wars becoming a primary strategy for smaller institutions competing for customers [6][22] Industry Evolution - The medical beauty industry is transitioning from an upstream-dominated model to one focused on terminal capabilities, with an emphasis on differentiation and scale as core competitive advantages [12][28] - Upstream companies are shifting their focus from licensing to product innovation, as competition intensifies and profit margins normalize [13][29] - The entry of public hospitals into the medical beauty sector is becoming a new variable, with a significant increase in the number of public hospitals establishing medical beauty departments [14][30] Consumer Behavior - Consumers are becoming more rational, shifting from a focus on appearance changes to daily anti-aging maintenance, with increased demands for product safety and institutional compliance [15][31] - This rationalization is driving industry upgrades, as institutions move towards standardized solutions that combine products, medical expertise, and post-operative management [15][31] - The transparency of industry information is improving, allowing consumers to compare the overall value of different institutions, which is pushing prices towards greater fairness [15][31]

头部医美机构春节消费情况交流 20260223 摘要 2026 年初线下医美终端机构营收呈现波动，1 月同比增长 11%，2 月 受春节影响同比下降 4%，前两月整体增长约 6%，客流量上升 10%， 但客单价持续下降。 轻医美占比提升导致单价下降，机构需引进高利润产品或设备以保持利 润空间。监管趋严促进合规，支持新产品审批，增值税增加压力但可通 过合理抵扣缓解。 非手术项目占比持续提升至 66%-70%，光电皮肤类项目占比稳定在 40%-45%，注射类项目不断增加。光电皮肤设备市场在紧致抗衰方面 需求较高，但客单价可能持续下降。 注射类产品线将显著增长，玻尿酸、新型肉毒素、重组胶原蛋白等不断 推出新产品。机构积极布局 OEM 代工贴牌定制，以降低成本并提高利 润率。 玻尿酸市场中，进口高端品牌仍受欢迎，但 OEM 定制贴牌玻尿酸逐渐 成为主推项目，增速显著。传统品牌增速放缓，差异化新品牌表现出色。 重组胶原蛋白市场增速显著，预计 2026 年保持强劲增长。锦波公司占 据重要地位，但新进入者将形成冲击，新产品上市将扩大市场份额。 肉毒素产品线稳定增长，新款肉毒素获批上市有望继续推动销量增长。 童颜针市场竞争稳 ...

Group 1 - The Hainan Province Danzhou Market Supervision Bureau and the Health Commission have launched a special inspection action focusing on the medical beauty market, particularly targeting various beauty institutions such as beauty salons and SPA centers [1] - A joint inspection team was formed to conduct surprise checks on 15 beauty establishments in the Nada Town area, assessing their qualifications, business projects, and the legality of their use of botulinum toxin and other prescription-required drugs [1] - During the inspections, enforcement personnel educated the responsible parties about relevant laws and regulations, emphasizing the legal responsibilities and safety requirements for using botulinum products [1] Group 2 - The market supervision department has reminded consumers that botulinum toxin injections are medical procedures that must be performed in licensed medical institutions by qualified physicians [2] - Consumers are advised to verify the qualifications of institutions and personnel before receiving services, ensuring the legality of the products used and retaining relevant evidence such as medical records and receipts [2] - The Danzhou Market Supervision Bureau plans to maintain a high-pressure regulatory stance, increasing daily supervision and special inspection efforts while enhancing collaboration with health and public security departments to purify the medical beauty market environment [2]

Core Insights - The medical beauty market is experiencing a surge in demand as consumers prepare for the upcoming Spring Festival, with many opting for aesthetic treatments to enhance their appearance [1][3]. Group 1: Market Trends - There has been a significant increase in user visits to medical beauty services, with Meituan reporting over a 15% year-on-year growth and nearly a 10% week-on-week increase [3]. - The demand for aesthetic treatments is primarily focused on anti-aging, wrinkle removal, and urgent skin condition improvement, with varying recovery periods influencing consumer choices [3]. - Popular treatments have shifted from longer recovery options like Thermage and Ultherapy to shorter recovery options such as hyaluronic acid injections and photorejuvenation [3]. Group 2: Company Initiatives - Meituan has launched a "Beautiful New Year" campaign, offering a 3000 yuan medical beauty voucher package and a beauty calendar to help users select appropriate treatments based on recovery times [3]. - During the Spring Festival, at least 30% of medical beauty institutions on the Meituan platform will remain open, which is a 5% increase compared to the previous year, providing convenience for users seeking urgent skin treatments [3]. - The company promotes the "Safe Beauty" initiative to ensure compliance and safety in the industry, aiming to verify over 12 million treatment instances by the end of 2025 across 2500 institutions in 140 cities [4].

Core Insights - The domestic medical beauty industry is undergoing a structural transformation in 2025, shifting from a "seller's market" to a "buyer's market" due to an increase in the supply of upstream products [1] - The approval of 52 new Class III medical device registrations in 2025 indicates a significant change in the supply-demand relationship within the industry [1] - Upstream manufacturers are compelled to adjust their competitive strategies, focusing on technological innovation, product iteration speed, and commercialization capabilities [1][4] Upstream Manufacturers - The competition among upstream manufacturers is intensifying as the medical beauty market continues to expand and diversify, with the industry size surpassing 300 billion yuan [3] - The light medical beauty market is expected to grow at a compound annual growth rate of over 20% in the next five years, becoming the mainstream segment [3] - Hyaluronic acid, botulinum toxin, collagen, and regenerative materials are projected to dominate the injection materials market in 2024, with respective market shares of 36%, 29%, 19%, and 16% [3] Product Supply Expansion - In 2025, 25 new Class III medical device registrations for hyaluronic acid products were approved, alongside approvals for collagen products, youth needles, and new materials like agarose and calcium phosphate [4] - Manufacturers are shifting from a "follow the trend" model to focusing on product innovation and expanding new indications, particularly in women's health-related aesthetics [4][5] Competitive Landscape - The competition is expected to transition from merely obtaining licenses to a focus on core technology, research efficiency, and understanding end-user needs [5] - The relationship between upstream manufacturers and downstream medical beauty institutions is evolving into a mutually beneficial partnership rather than a zero-sum game [6] Downstream Institutions - The approval of 52 new Class III medical device registrations has provided downstream institutions with greater product selection and negotiating power with upstream manufacturers [6] - New Oxygen's introduction of competitively priced products has sparked controversy among upstream manufacturers, highlighting the ongoing price competition in the market [6] Market Dynamics - Public hospitals are increasingly entering the medical beauty sector, with 203 hospitals opening or establishing medical beauty departments in 2025, a 229% increase from the previous year [8] - Major internet platforms like Meituan and Tmall are leveraging their traffic advantages to enhance the medical beauty sector, intensifying market competition [8] - The future of the medical beauty industry is expected to be characterized by a diverse and competitive landscape, where trust and professional credibility are crucial for consumer acceptance [8]

Core Insights - The medical beauty market is experiencing a surge in demand as consumers prepare for the upcoming Spring Festival, with many opting for aesthetic treatments to enhance their appearance [1][2]. Group 1: Market Trends - There is a notable shift in consumer behavior, with traditional beauty treatments being supplemented by light medical beauty procedures, forming a new "Spring Festival beauty package" [1]. - Meituan's data indicates a more than 15% year-on-year increase in user visits to medical beauty services, with a nearly 10% week-on-week growth, reflecting heightened market activity [1]. - The demand is primarily focused on anti-aging, wrinkle removal, and skin emergency treatments, with varying popularity based on recovery times [1]. Group 2: Treatment Popularity - Treatments like Thermage and Ultherapy peaked in early January but have seen a gradual decline, while hyaluronic acid, Botox, and photorejuvenation have been on the rise recently [1]. - Meituan has launched a "Beautiful New Year" campaign, offering a 3000 yuan medical beauty voucher package and a beauty calendar to help users choose suitable treatments [1]. Group 3: Operational Insights - During the Spring Festival, at least 30% of medical beauty institutions on the Meituan platform will remain open, an increase of about 5 percentage points from the previous year, providing convenience for users seeking treatments [2]. - Meituan is promoting the "Safe Beauty" initiative to ensure compliance and safety in the industry, aiming to have over 12 million verified treatments by the end of 2025, covering 2500 institutions across 140 cities [3].

Core Viewpoint - Wang Sicong is quietly executing a strategic "divestment" and "rebirth" of his business assets, moving away from his previous ventures in the entertainment industry towards new opportunities in the medical beauty sector [2][4]. Group 1: Business Divestment - Beijing Pusi Investment Co., Ltd., wholly owned by Wang Sicong, had its 8% stake in Shanghai Maijie Culture announced for judicial auction, with a starting price of only 10.75 thousand yuan, while the assessed value was negative at -166.62 thousand yuan [2][3][10]. - The auction reflects a typical "cut loss" strategy, aiming to alleviate Wang Sicong's personal debt pressure by shedding underperforming assets [10][11]. - The Maijie Culture project, once valued at over 250 billion yuan, faced significant operational challenges leading to its decline, including layoffs and store closures [8][10]. Group 2: New Business Ventures - Concurrently with the auction, a new entity, Beijing Ningyue Medical Beauty Clinic, was registered, with Wang Sicong indirectly holding shares through Pusi Capital [11][12]. - This new venture is seen as a "shell rebirth," allowing Wang to distance himself from past liabilities while entering the medical beauty market [11][12]. - The medical beauty industry presents both opportunities and challenges, with Wang Sicong leveraging his celebrity connections to reduce customer acquisition costs significantly [15][18]. Group 3: Industry Challenges - The medical beauty sector has become increasingly competitive, with a significant number of companies shutting down, indicating a saturated market [22][28]. - The industry faces a "customer acquisition death spiral," where rising costs for customer acquisition threaten profit margins, with current costs reaching 800-1200 yuan per customer [26][28]. - Wang Sicong's previous failures in the medical beauty space highlight the need for a shift from a marketing-heavy approach to a focus on operational efficiency and quality [19][28].

Group 1 - The core focus of Jiangsu's public security efforts is on combating crimes in the food, drug, environmental, and intellectual property sectors, with a significant reduction in reported cases and arrests this year [1] - A total of 2,767 criminal cases related to food, drug, and environmental issues were handled, resulting in the arrest of 6,444 suspects, with reported cases and crime rates decreasing by 22.5% and 22% respectively compared to the previous year [1] - The "Kunlun" special operation has been ongoing for seven years, maintaining a strong crackdown on prominent crimes in the food, drug, and environmental sectors [1] Group 2 - Jiangsu's public security is actively addressing crimes that infringe upon the rights of vulnerable groups, including the elderly, women, and children, with a focus on specific products such as botulinum toxin and cosmetics [2] - The province has established a rapid testing system with three central laboratories and 59 quick testing rooms, enabling comprehensive coverage and coordinated efforts across the province [2] - Regular undercover inspections and follow-up investigations have led to the resolution of 71 cases based on abnormal test results [2]

Core Insights - The "light medical beauty" market in China has rapidly penetrated modern life, with treatments like photon rejuvenation and water light needles becoming accessible during short breaks, reflecting a shift in consumer behavior and preferences [1][3][4] - The market has evolved significantly over the past decade, with a growing user base and increasing market transparency, leading to a projected user scale of 31.05 million by 2025 [1][2] - The industry is experiencing consolidation, with small institutions facing challenges due to increased competition from new players like New Oxygen and JD Health, indicating a trend towards chain operations and larger entities [2][12] Market Growth and Trends - The user scale of China's light medical beauty market reached 23.54 million in 2023, with expectations to grow to 31.05 million by 2025 [1] - The medical beauty market size is projected to increase from 227.4 billion yuan in 2021 to 364 billion yuan by 2025, with light medical beauty accounting for 53.3% of the market [1] - The consumer demographic has expanded from a niche market to a broader age range, including Z generation to individuals over 40, indicating a shift towards a more inclusive consumer base [5][12] Consumer Behavior and Preferences - There is a notable shift in consumer preferences from "internet celebrity faces" to more natural aesthetics, with 78% of consumers seeking natural results [4][5] - Male consumers are emerging as a significant growth segment, with their share in the medical beauty market increasing from 14% to 29% between 2022 and 2025 [5][6] - Consumers are increasingly prioritizing quality and personalized aesthetic design over mere procedural outcomes, reflecting a maturation in consumer awareness [4][10] Product and Service Evolution - The market has seen a shift in dominant products, with botulinum toxin and hyaluronic acid remaining the leading choices, while regenerative materials are gaining traction [6][7] - Regenerative materials, such as polylactic acid and recombinant collagen, are being introduced, but experts believe hyaluronic acid will maintain its dominant position due to its established safety and effectiveness [7][8] - The price of medical beauty services is becoming more transparent, with significant reductions in costs for treatments like photon rejuvenation, making them more accessible to a wider audience [10][11] Industry Dynamics and Future Outlook - The medical beauty industry is undergoing significant restructuring, with a high turnover rate of institutions and a trend towards professional consolidation [12][13] - Future industry developments are expected to focus on chain operations, involvement of listed companies, and participation of state-owned capital, enhancing trust and operational efficiency [13][14] - The market is anticipated to continue evolving towards a dual-track model of professionalization and market segmentation, with large chains dominating standardized treatments while niche clinics focus on personalized services [14]

Core Insights - The Chinese medical aesthetics industry has surpassed 300 billion yuan, with the light medical aesthetics market expected to grow at a compound annual growth rate (CAGR) of over 20% in the next five years, becoming the mainstream segment by 2024 [1] - Injection projects, as the core growth engine of light medical aesthetics, have seen their market size grow from 25.7 billion yuan in 2018 to 67 billion yuan in 2023, with a CAGR of 21.1%, projected to reach 147 billion yuan by 2027 [1] - The industry faces challenges such as rapid market changes driven by consumer preferences and increasing competition, necessitating innovation in material research to build competitive barriers [1] Market Dynamics - In 2024, the market share of injection materials is projected to be approximately 36% for hyaluronic acid, 29% for botulinum toxin, 19% for collagen, and 16% for regenerative materials [3] - The competition in the hyaluronic acid market has intensified, leading to revenue declines for major companies like Huaxi Biological and Aimeike, with revenue drops of 18.36% and 21.49% respectively in the first three quarters of 2025 [3][4] - In contrast, the recombinant collagen market is rapidly growing, with a projected CAGR of 44.93%, expected to reach 58.57 billion yuan by 2025 [3] Innovation and Product Development - Companies are accelerating new product launches to capture market opportunities, with Huaxi Biological introducing compliant products for facial skin improvement and other companies like Jinbo Biological launching innovative recombinant collagen products [5] - The emergence of new materials such as alginate and hydroxyapatite is set to enrich the market supply, with several products receiving regulatory approval in 2025 [6] Regulatory Environment - The industry is experiencing a shift towards compliance, with increased regulatory scrutiny leading to a "survival of the fittest" scenario, pushing medical aesthetic institutions to accelerate compliance transformations [2] - Despite the growth in compliant products, issues such as illegal operations and counterfeit products remain prevalent, posing risks to consumer safety [11][12] Pricing and Market Structure - The supply expansion has led to a restructuring of interests within the industry, with upstream manufacturers and downstream medical institutions engaged in pricing power struggles [8][9] - New platforms like Xinyang are disrupting traditional pricing models by significantly reducing costs through digitalization and centralized procurement, indicating a shift from a seller's market to a buyer's market [9][10] Future Trends - The industry is expected to evolve towards a more transparent and competitive landscape, with a focus on product and scenario-driven strategies, comprehensive treatment solutions, and enhanced consumer awareness [10] - The ongoing regulatory efforts and market dynamics suggest that the medical aesthetics industry is moving towards a more mature and compliant operational model, emphasizing innovation and safety [14]